A Phase I, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EMA401 Following Single Ascending Oral Dosing of EMA401.Na in Healthy Volunteers Administered Orally in the Fasted and Fed State.

Inclusion Criteria8

• Healthy subjects- defined as individuals who are free from clinically significant illnesss or disease as determined by their medical / surgical history, physical examination (including height & weight), 12 lead electrocardiogram (ECG) and clincial laboratory determinations.
• Normotensive - Systolic between 90 and 140 mmHg, diastolic between 60 & 90 mmHg.
• No clincially relevant abnormality in an electrocardiogram (ECG) - QTc < 450ms, PR interval 120-210 ms, QRS duration <100ms. (QTc = QT interval corrected for heart rate, where QT = a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, PR interval = measured from the beginning of the P wave to the beginning of the QRS complex and QRS duration (complex) = a structure on the ECG that corresponds to the depolarization of the ventricles.
• Resting pulse rate - between 40 and 100 bpm
• Body Mass Index (BMI)- between 19 and 30 kg/m2
• Human Immunodefeciency Virus (HIV), Hepatitis B virus and Hepatitis C virus negative
• Smoked less than 5 cigarettes or equivalent per month in last 12 months.
• Agrees to use 2 methods of contraception during study.